EATG » HIV treatment

HIV treatment

Kazakhstan community experts discussed the mechanisms for expanding access to the modern HIV treatment with the state officials

Representatives of patient communities, NGOs and state institutions of Kazakhstan, international agencies and organizations held a meeting on January 16 to discuss the results of the ART Availability Overview in…

HIV i-Base: HIV Treatment Bulletin, 22 January 2018

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. The publication started 2018 with a new look: Faster, shorter, more frequent – yet just as cutting edge……

Long-acting injectable ARVs are convenient and private, study participants report

HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling that it eliminated…

HIV i-Base: HIV Treatment Bulletin, 5 January 2018

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. The publication starts 2018 with a new look: Shorter… faster… more often… More information here. The online version…

NIH study supports use of short-term HIV treatment interruption in clinical trials

Findings may aid design of trials to assess strategies to control HIV without drugs. A short-term pause in HIV treatment during a carefully monitored clinical trial does not lead to…

Merck submits New Drug Applications for doravirine to FDA

FDA accepts New Drug Applications for Merck’s doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), for treatment of HIV-1 infection KENILWORTH, N.J., January 8, 2018 - Merck (NYSE:MRK), known…

Suboptimal ART adherence associated with greater inflammation in patients with HIV

Recently published findings indicate that suboptimal adherence to ART is associated with activation of coagulation and enhanced residual inflammation among patients with HIV, even if patients have already achieved virologic…

Immediate HIV treatment has little impact on risk of future drug resistance

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the…

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound…

Diabetes in people with HIV over 50 overwhelmingly linked to old antiretrovirals, not age or body weight

People with HIV over the age of 50 are more likely to have developed type 2 diabetes if they started antiretroviral treatment before 1999 or had a longer exposure to…

1 2 3 44